All news

Johnson & Johnson (JNJ) Backs Prostate Cancer Device Development

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Johnson & Johnson (JNJ) has invested in Francis Medical to support the development of the Vanquish prostate cancer ablation device, a minimally invasive water vapor system. This move, alongside positive Phase 2 DAHLIAS trial results for nipocalimab in Sjögren's disease, aligns with J&J's strategy to bolster its Innovative Medicine and MedTech pipeline, particularly in immunology and oncology.

Read original source

JNJ company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.